InMed Pharmaceuticals Inc. (NASDAQ:INM) Sees Significant Growth in Short Interest

InMed Pharmaceuticals Inc. (NASDAQ:INM) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 115,500 shares, a growth of 188.8% from the October 15th total of 40,000 shares. Based on an average trading volume of 6,410,000 shares, the short-interest ratio is presently 0.0 days.

InMed Pharmaceuticals Stock Up 3.3 %

Shares of InMed Pharmaceuticals stock opened at $0.25 on Wednesday. The company has a quick ratio of 3.78, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. InMed Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $0.78. The company has a market cap of $3.36 million, a price-to-earnings ratio of -0.19 and a beta of 0.36. The company’s 50 day moving average is $0.25 and its 200 day moving average is $0.26.

InMed Pharmaceuticals (NASDAQ:INM) last released its quarterly earnings results on Friday, September 27th. The company reported ($0.19) earnings per share for the quarter. InMed Pharmaceuticals had a negative net margin of 166.94% and a negative return on equity of 71.97%. The firm had revenue of $1.28 million for the quarter.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.